Latest News

November 18, 2016

New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes

Study results suggesting that T cell exhaustion markers may be correlated with treatment response in type 1 diabetes (T1D) patients from the Immune Tolerance Network’s AbATE study were published today in Science Immunology. This research, led by Alice Long, PhD, and Peter Linsley, PhD, at Benaroya Research Institute, used integrated systems biology and flow cytometry approaches to investigate pathways associated with C-peptide stabilization in responders to anti-CD3 treatment.

August 3, 2016

Abatacept in Relapsing-Remitting Multiple Sclerosis

Abatacept (Orencia®; Bristol-Myers Squibb) did not reduce the number of new gadolinium-enhancing Magnetic Resonance Imaging (MRI) lesions in patients with relapsing-remitting multiple sclerosis compared to a placebo after 24 weeks.

July 7, 2016

ITN Opens ALLTOL Study for Organ Transplant Recipients

The Immune Tolerance Network (ITN) opened up a new observational transplant trial, ALLTOL, with the enrollment of its first two participants at the University of California, San Francisco (UCSF) June 30, 2016. ALLTOL is a prospective cohort study to enroll “operationally tolerant” kidney and liver transplant recipients who have successfully discontinued immunosuppressive medications and continue to have normal function in their transplanted organ.

June 23, 2016

Five Year Follow-up of WISP-R Pediatric Liver Transplant Recipients

The 12 young liver transplant recipients in the Immune Tolerance Network’s WISP-R Study (Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients) show no immunological or histological signs of rejection four years after coming off all immunosuppressive medications. The data were published last week in Hepatology.WISP-R is a multi-center, single arm pilot study that assessed immunosuppression withdrawal in stable pediatric liver transplant recipients with a parental living donor.

June 20, 2016

Reduced Hypoglycemic Events and Improved Glycemic Variability is Associated with C-peptide Preservation in New-Onset Type 1 Diabetes Patients in the T1DAL Study

Better blood glucose control is correlated with C-peptide preservation, a marker of natural insulin production, in individuals with type 1 diabetes who participated in the Immune Tolerance Network’s T1DAL Study [Inducing Remission in New Onset T1DM with Alefacept (Amevive®)]. This secondary analysis of T1DAL data is the first to demonstrate the correlation between insulin preservation and glycemic control in a clinical trial with an immune-targeting drug in type 1 diabetes.

June 16, 2016

Nutritional Impact of Peanut Consumption in the LEAP Study

Introducing peanut to young infants in the LEAP peanut allergy prevention study did not negatively impact duration of breast feeding, nutritional intake, or growth five years later.

May 18, 2016

ITN's LEAP Study Recognized by Society for Clinical Trials

The ITN’s LEAP study won the Society for Clinical Trials David Sackett Trial of the Year Award for 2015. This award goes to a randomized clinical trial published in the previous year that supports substantial change in healthcare, reflects excellent methodology, and overcomes obstacles in implementation. Congratulations to the LEAP team for this recognition! 

April 21, 2016

Antithymocyte Globulin in Type 1 Diabetes: Two-Year Results from the START Study

Two-year data from the ITN’s START Trial (Study of Thymoglobulin to ARest T1D) found that antithymocyte globulin (ATG) did not preserve insulin production in the majority of type 1 diabetes patients, but did show benefit in a subset of older participants. The results were published recently in Diabetalogia.The START Trial, led by Dr.

April 12, 2016

PAUSE Psoriasis Trial Completes Enrollment

The Immune Tolerance Network completed enrollment for the PAUSE psoriasis study with 108 participants. Led by Dr. James Krueger at the Rockefeller University, the PAUSE Study is testing the combination of two biologics, ustekinumab (Janssen Biotech, Inc.) and abatacept (Bristol-Myers Squibb), in psoriasis patients.

March 4, 2016

Protection against peanut allergy by early consumption persists following a one-year period of peanut avoidance

The Immune Tolerance Network’s (ITN) LEAP-ON clinical trial has found that peanut allergy prevention achieved from early peanut consumption in at-risk infants persists after a one-year period of avoiding peanut. LEAP-ON (Persistence of Oral Tolerance to Peanut) was led by Dr.